Drug Profile
NV 04
Alternative Names: Trans NV-04; NV-04Latest Information Update: 12 Dec 2017
Price :
$50
*
At a glance
- Originator Novogen
- Developer Baker Medical Research Institute; Heart Research Institute; Howard Florey Institute
- Class Cardiovascular therapies; Isoflavones; Vasodilators
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cardiovascular-disorders in Australia (Intra-arterial)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cardiovascular-disorders in Australia (PO)
- 19 Mar 2007 Clinical development is ongoing for NV 04 in Cardiovascular disorders